[Form 4] PTC Therapeutics, Inc. Insider Trading Activity

Insider Trade Summary

Net Seller: 10,739 shares ($555,636)

Net Sell 2 txns

Insider Klein Matthew B.

Role CHIEF EXECUTIVE OFFICER

Sold 10,739 shs ($556K)

Type	Security	Shares	Price	Value
Sale	Common Stock	10,739	$51.74	$556K
Grant/Award	Common Stock	75,000	$0.00	--

Holdings After Transaction: Common Stock — 337,767 shares (Direct)

Footnotes (1)

1. Represents the number of shares of the Issuer's common stock underlying restricted stock units ("RSUs") earned upon the vesting of performance-based restricted stock units ("PSUs") granted in December 2023. On August 1, 2025, the Issuer's board of directors certified the Issuer's achievement of a pre-established regulatory milestone set forth in the PSUs, which resulted in the reported RSUs being earned. Each earned RSU represents the contingent right to receive one share of the Issuer's common stock upon vesting. The earned RSUs immediately vested as to 25,000 shares on August 1, 2025 in connection with being earned and are scheduled to vest with respect to the remaining 50,000 shares in equal annual installments on August 1, 2026 and August 1, 2027. Includes 272 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended June 30, 2025. Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the RSU grant to satisfy tax withholding obligations in connection with the vesting of the earned RSUs with respect to 25,000 shares on August 1, 2025.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Klein Matthew B.

(Last) (First) (Middle)

C/O PTC THERAPEUTICS, INC.

500 WARREN CORPORATE CENTER DRIVE

(Street)

WARREN NJ 07059

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
08/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/01/2025		A		75,000(1)	A	$0	348,506(2)	D
Common Stock	08/05/2025		S(3)		10,739	D	$51.74	337,767	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares of the Issuer's common stock underlying restricted stock units ("RSUs") earned upon the vesting of performance-based restricted stock units ("PSUs") granted in December 2023. On August 1, 2025, the Issuer's board of directors certified the Issuer's achievement of a pre-established regulatory milestone set forth in the PSUs, which resulted in the reported RSUs being earned. Each earned RSU represents the contingent right to receive one share of the Issuer's common stock upon vesting. The earned RSUs immediately vested as to 25,000 shares on August 1, 2025 in connection with being earned and are scheduled to vest with respect to the remaining 50,000 shares in equal annual installments on August 1, 2026 and August 1, 2027.

2. Includes 272 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended June 30, 2025.

3. Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the RSU grant to satisfy tax withholding obligations in connection with the vesting of the earned RSUs with respect to 25,000 shares on August 1, 2025.

	/s/ Avraham S. Adler, Attorney-in-Fact	08/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.